Acromegaly in a multiple endocrine neoplasia type 1 (MEN 1) family with low penetrance of the disease

European Journal of Endocrinology

Volumn 153, Issue 6, 2005, Pages 741-746

  Dreijerink, Koen M A ^a   van Beek, André P ^b   Lentjes, Eef G W M ^a   Post, Jan G ^a   van der Luijt, Rob B ^a   Canninga van Dijk, Marijke R ^a   Lips, Cornelis J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; GENE MUTATION; GERM LINE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; INTRON; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID ADENOMA; PATHOPHYSIOLOGY; PATIENT MONITORING; PEDIGREE ANALYSIS; PENETRANCE; PRIORITY JOURNAL;

ACROMEGALY; ADENOMA; DNA MUTATIONAL ANALYSIS; GERM-LINE MUTATION; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PARATHYROID NEOPLASMS; PEDIGREE; PENETRANCE;

EID: 29644442002     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02022     Document Type: Article

References (34)

1. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr & Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671.
2. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL & Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997 276 404-407.
3. Lemmens I, Van De Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, Pugeat M, Calender A, Parente F, Quincey D, Gaudray P, De Wit MJ, Lips CJ, Hoppener JW, Khodaei S, Grant AL, Weber G, Kytola S, Teh BT, Farnebo F & Thakker RV. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Human Molecular Genetics 1997 6 1177-1183.
4. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel a M, Collins FS & Chandrasekharappa SC. Menin, the product of the MEN1 gene, is a nuclear protein. PNAS 1998 95 1630-1634.
5. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ & Burns AL. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999 96 143-152.
6. Kaji H, Canaff L, Lebrun JJ, Goltzman D & Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. PNAS 2001 98 3837-3842.
7. Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ & Burns AL. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001 20 4917-4925.
8. Geerdink EA, Van Der Luijt RB & Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? European Journal of Endocrinology 2003 149 577-582.
9. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A & Thakker RV. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quarterly Journal of Medicine 1996 89 653-669.
10. Carty SE, Helm AK, Amico JA, Clarke MR, Foley TP, Watson CG & Mulvihill JJ. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998 124 1106-1113.
11. Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding C, Harding B, Besser GM, Edwards CR, Monson JP, Sampson J, Wass JA, Wheeler MH & Thakker RV. Characterization of mutations in patients with multiple endocrine neoplasia type 1. American Journal of Human Genetics 1998 62 232-244.
12. Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir GM, Zhang CX, Porchet N, Cordier M, Beroud C & Calender A. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Human Mutation 2002 20 35-47.
13. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ & Evans DB. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Archives of Surgery 2002 137 641-647.
14. Pannett AA, Kennedy AM, Turner JJ, Forbes SA, Cavaco BM, Bassett JH, Cianferotti L, Harding B, Shine B, Flinter F, Maidment CG, Trembath R & Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clinical Endocrinology 2003 58 639-646.
15. Olufemi SE, Green JS, Manickam P, Guru SC, Agarwal SK, Kester MB, Dong Q, Burns AL, Spiegel AM, Marx SJ, Collins FS & Chandrasekharappa SC. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Human Mutation 1998 11 264-269.
16. Roijers JF, De Wit MJ, Van Der Luijt RB, Ploos Van Amstel HK, Hoppener JW & Lips CJ. Criteria for mutation analysis in MEN 1 suspected patients: MEN 1 case-finding. European Journal of Clinical Investigation 2000 30 487-492.
17. Shapiro MB & Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Research 1987 15 7155-7174.
18. Brunak S, Engelbrecht J & Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. Journal of Molecular Biology 1991 220 49-65.
19. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465.
20. Mayr B, Brabant G & Von Zur Muhlen A. Menin mutations in MEN1 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 3004-3005.
21. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ & Robinson BG. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 2003 22 1358-1364.
22. Alexander L, Appleton D, Hall R, Ross WM & Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology 1980 12 71-79.
23. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS & Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Annals of Internal Medicine 1998 129 484-494.
24. O'Brien T, O'Riordan DS, Gharib H, Scheithauer BW, Ebersold MJ & Van Heerden JA. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery 1996 39 273-278.
25. Bertherat J, Turpin G, Rauch C, Li JY, Epelbaum J, Sassolas G & Schaison G. Presence of somatostatin receptors negatively coupled to adenylate cyclase in ectopic growth hormone-releasing hormone- and alpha-subunit-secreting tumors from acromegalic patients responsive to octreotide. Journal of Clinical Endocrinology and Metabolism 1994 79 1457-1464.
26. Shintani Y, Yoshimoto K, Horie H, Sano T, Kanesaki Y, Hosoi E, Yokogoshi Y, Bando H, Iwahana H & Kannuki S. Two different pituitary adenomas in a patient with multiple endocrine neoplasia type 1 associated with growth hormone-releasing hormone-producing pancreatic tumor: clinical and genetic features. Endocrine Journal 1995 42 331-340.
27. Liu SW, Van De Velde CJ, Heslinga JM, Kievit J & Roelfsema F. Acromegaly caused by growth hormone-relating hormone in a patient with multiple endocrine neoplasia type I. Japanese Journal of Clinical Oncology 1996 26 49-52.
28. Boix E, Pico A, Pinedo R, Aranda I & Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clinical Endocrinology 2002 57 131-134.
29. Melmed S. Acromegaly. New England Journal of Medicine 1990 322 966-977.
30. Stratakis CA, Schussheim DH, Freedman SM, Keil MF, Pack SD, Agarwal SK, Skarulis MC, Weil RJ, Lubensky IA, Zhuang Z, Oldfield EH & Marx SJ. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism 2000 85 4776-4780.
31. Beckers A, Betea D, Socin HV & Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. Journal of Internal Medicine 2003 253 599-605.
32. Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA & Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). Journal of Clinical Endocrinology and Metabolism 2000 85 3860-3865.
33. Stratakis CA, Kirschner LS & Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. Journal of Clinical Endocrinology and Metabolism 2001 86 4041-4046.
34. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG & Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 5104-5112.